PTPRC and myeloid sarcoma: In relative numbers, comparing labelled lEVs to all events in the lEVs gate, MS patients had a significantly lower number of lEVs of endothelial origin (CD105+: 4.5% vs. 7.6%; p = 0.0135), leukocyte origin (CD45+: 8.4% vs. 12.3%; p = 0.0421), B-lymphocyte origin (CD19+: 3.4% vs. 6.7%; p = 0.0362) and T-lymphocyte origin (CD3+: 7.1% vs. 14.3%; p = 0.0048 or CD45+CD3+: 4.1% vs. 7.4%; p = 0.0202) as shown in dot plots in Figure 5 and Figure S4.